Varian and the Cincinnati Children's/UC Health Proton Therapy Center Announce Initial Patient Treated in the FAST-01 First Human Clinical Trial of FLASH Therapy for Cancer
Varian (NYSE: VAR) and Cincinnati Children's/UC Health Proton Therapy Center have launched the first clinical trial of FLASH therapy, marking a significant milestone. The FAST-01 study aims to enroll up to 10 patients with bone metastases to evaluate the feasibility, side effects, and efficacy of ultra-high dose radiation therapy. The initial patient was treated this week, with plans to extend FLASH therapy to other cancers. Experts express optimism that this approach could revolutionize cancer care by reducing side effects while increasing treatment effectiveness.
- Launch of the FAST-01 trial for FLASH therapy, first in human trial.
- Initial patient treated successfully, reflecting progress in cancer treatment.
- Potential to improve efficacy and reduce side effects for cancer patients.
- Expert collaboration among leading centers enhancing research credibility.
- None.
PALO ALTO, Calif., and CINCINNATI, Ohio, Nov. 19, 2020 /PRNewswire/ -- Varian (NYSE: VAR) and the Cincinnati Children's/UC Health Proton Therapy Center today announce the start of the first clinical trial of FLASH therapy as part of the recently opened FAST-01 study (FeAsibility Study of FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases). The clinical trial involves the investigational use of Varian's ProBeam® particle accelerator modified to enable radiation therapy delivery at ultra-high dose rates (dose delivered in less than 1 second) and is being conducted at the Cincinnati Children's/UC Health Proton Therapy Center with John C. Breneman M.D., Medical Director of the center, serving as principal investigator.
The first clinical trial patient was treated this week. The FAST-01 study is expected to enroll up to 10 patients with bone metastases to evaluate clinical workflow feasibility, treatment-related side effects, and efficacy of treatment as assessed by measuring pain relief of trial participants. The clinical trial, informed by years of preclinical work, was designed by experts at Varian and multiple centers in the FlashForwardTM Consortium, including Cincinnati's Children's/UC Health Proton Therapy Center and the New York Proton Center.
"Treating the first patient in this FLASH clinical trial is a milestone that many thought was still years ahead of us," said Kolleen Kennedy, Chief Growth Officer and President of Proton Therapy Solutions at Varian. "There was overwhelming support from Dr. Breneman and his team for this clinical trial, which was designed in collaboration with the FlashForward Consortium and with significant contributions from the New York Proton Center. These efforts help Varian safely advance potential therapy options towards our vision of a world without fear of cancer."
Breneman noted that, because this is the first in human trial of FLASH radiotherapy, it will build a foundation for extending this therapy to other types of cancer treatments.
"Trials using FLASH radiotherapy for lung cancer and other malignancies are currently being developed," said Breneman, a UC Health radiation oncologist and a professor emeritus at the University of Cincinnati College of Medicine. "Using FLASH treatment for these cancers could deliver higher cancer-killing doses without causing inordinate side effects, which would be a real advance."
"FLASH therapy has the potential to be practice changing and dramatically improve the experience of cancer care for a new generation of patients. The launch of the first FLASH clinical trial, a project that has come to fruition after years of intensive study, is an important milestone in the progress of radiation therapy," said FlashForward Consortium member Dr. Charles B. Simone, II, FACRO, Chief Medical Officer at New York Proton Center. "We are optimistic that the results of the FAST clinical development program will transform the way the industry approaches treatment. The New York Proton Center is proud to be a partner in this future-focused study."
John Perentesis, MD, Director of the Division of Oncology & Cancer Programs at Cincinnati Children's, said FLASH is potentially a transformational advance for cancer treatment for many patients."If the side effects of radiation on the normal tissues surrounding a tumor can be significantly reduced, the dose of radiation to treat a cancer can be greatly increased," Perentesis said. "This would raise hope to cure malignancies that respond to radiation but aren't completely cured at current doses, including pediatric brain tumors like DIPG/pontine glioma and medulloblastoma, sarcomas, and neuroblastoma."
About Varian
At Varian, we envision a world without fear of cancer. For more than 70 years, we have developed, built and delivered innovative cancer care technologies and solutions for our clinical partners around the globe to help them treat millions of patients each year. With an Intelligent Cancer Care approach, we are harnessing advanced technologies like artificial intelligence, machine learning and data analytics to enhance cancer treatment and expand access to care. Our 10,000 employees across 70 locations keep the patient and our clinical partners at the center of our thinking as we power new victories in cancer care. Because, for cancer patients everywhere, their fight is our fight. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter.
About the Cincinnati Children's/UC Health Proton Therapy Center
The Cincinnati Children's/UC Health Proton Therapy Center, which opened in 2016, is one of only 35 in the United States. The Cincinnati center incorporates a
About New York Proton Center
The New York Proton Center is creating the gold standard for proton therapy, giving new hope to patients living with cancer. In partnership with leading academic medical centers—Memorial Sloan Kettering Cancer Center, Montefiore Health System, Mount Sinai Health System, and ProHEALTH as manager—the New York Proton Center brings together expert oncologists, clinical care teams, and researchers to improve cancer care and advance the clinical evidence for proton therapy.
About ProBeam®
Varian's ProBeam proton therapy system is a cancer treatment system that uses protons rather than X-rays to treat cancerous tumors with great precision. It is effective for certain types of cancers and can treat with a high dose of radiation to the tumor, while delivering lower radiation to the surrounding healthy tissue.
Press Contacts | Investor Relations Contact |
Aimee Corso Health + Commerce on behalf of Varian +1 (310) 780-2661 | Anshul Maheshwari Vice President, Investor Relations +1 (650) 424-5631 |
Barrett J. Brunsman Cincinnati Children's | |
Nathaniel Goehring +1 (781) 608-8437 BerlinRosen on behalf of NY Proton Therapy Center |
View original content to download multimedia:http://www.prnewswire.com/news-releases/varian-and-the-cincinnati-childrensuc-health-proton-therapy-center-announce-initial-patient-treated-in-the-fast-01-first-human-clinical-trial-of-flash-therapy-for-cancer-301176678.html
SOURCE Varian
